75 related articles for article (PubMed ID: 15915006)
1. Modulite: a simple solution to a difficult problem.
Lewis DA; Ganderton D; Meakin BJ; Brambilla G
Respiration; 2005; 72 Suppl 1():3-5. PubMed ID: 15915006
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
3. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
Langley SJ; Houghton CM; Singh SD
Respiration; 2005; 72 Suppl 1():35-7. PubMed ID: 15915011
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
[TBL] [Abstract][Full Text] [Related]
5. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D; Vicaut E; Lefrançois G;
Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
[TBL] [Abstract][Full Text] [Related]
6. The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler.
Ganderton D; Lewis D; Davies R; Meakin B; Church T
Respir Med; 2003 Nov; 97 Suppl D():S4-9. PubMed ID: 14753246
[TBL] [Abstract][Full Text] [Related]
7. Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers.
Adi H; Young PM; Traini D
J Pharm Pharmacol; 2012 Sep; 64(9):1245-53. PubMed ID: 22881437
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
Molimard M; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():28-34. PubMed ID: 15915010
[TBL] [Abstract][Full Text] [Related]
9. In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers.
Traini D; Young PM; Rogueda P; Price R
Pharm Res; 2007 Jan; 24(1):125-35. PubMed ID: 17103336
[TBL] [Abstract][Full Text] [Related]
10. A novel formulation technique for metered dose inhaler (MDI) suspensions.
Steckel H; Wehle S
Int J Pharm; 2004 Oct; 284(1-2):75-82. PubMed ID: 15454299
[TBL] [Abstract][Full Text] [Related]
11. The CFC to HFA transition and its impact on pulmonary drug development.
Leach CL
Respir Care; 2005 Sep; 50(9):1201-8. PubMed ID: 16122403
[TBL] [Abstract][Full Text] [Related]
12. Modulite technology in the development of formoterol HFA pMDI: clinical evidence and future opportunities.
Bousquet J; Dell'anna C
Expert Rev Respir Med; 2008 Feb; 2(1):27-36. PubMed ID: 20477219
[TBL] [Abstract][Full Text] [Related]
13. Metered-dose inhalers, dry powder inhalers, and transitions.
Fink JB
Respir Care; 2000 Jun; 45(6):623-35. PubMed ID: 10894455
[TBL] [Abstract][Full Text] [Related]
14. High-pressure aerosol suspensions--a novel laser diffraction particle sizing system for hydrofluoroalkane pressurised metered dose inhalers.
Jones SA; Martin GP; Brown MB
Int J Pharm; 2005 Sep; 302(1-2):154-65. PubMed ID: 16102928
[TBL] [Abstract][Full Text] [Related]
15. The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler.
Saadat A; Zhu B; Haghi M; King G; Colombo G; Young PM; Traini D
J Pharm Pharmacol; 2014 May; 66(5):639-45. PubMed ID: 24329164
[TBL] [Abstract][Full Text] [Related]
16. A switch to eco-friendly inhalers.
Johns Hopkins Med Lett Health After 50; 2009 Mar; 21(1):2. PubMed ID: 19370797
[No Abstract] [Full Text] [Related]
17. CFC Phase-Out and the Chiesi Solution.
Huchon G; Fabbri LM
Respiration; 2005; 72 Suppl 1():1-2. PubMed ID: 15915005
[No Abstract] [Full Text] [Related]
18. Evaluation of metered dose inhaler spray velocities using phase Doppler anemometry (PDA).
Liu X; Doub WH; Guo C
Int J Pharm; 2012 Feb; 423(2):235-9. PubMed ID: 22183132
[TBL] [Abstract][Full Text] [Related]
19. The ester group: how hydrofluoroalkane-philic is it?
Peguin RP; Wu L; da Rocha SR
Langmuir; 2007 Jul; 23(16):8291-4. PubMed ID: 17602576
[TBL] [Abstract][Full Text] [Related]
20. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers.
Smyth HD
Adv Drug Deliv Rev; 2003 Jul; 55(7):807-28. PubMed ID: 12842602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
